Revisiting neoadjuvant therapy in non-small-cell lung cancer

SPL Saw, BH Ong, KLM Chua, A Takano… - The Lancet …, 2021 - thelancet.com
Despite the rapidly evolving treatment landscape in advanced non-small-cell lung cancer
(NSCLC), developments in neoadjuvant and adjuvant treatments have been nascent by …

Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials

Z Niu, R Jin, Y Zhang, H Li - Signal Transduction and Targeted Therapy, 2022 - nature.com
Lung cancer is the leading cause of cancer-related death across the world. Unlike lung
adenocarcinoma, patients with lung squamous cell carcinoma (LSCC) have not benefitted …

A targetable CoQ-FSP1 axis drives ferroptosis-and radiation-resistance in KEAP1 inactive lung cancers

P Koppula, G Lei, Y Zhang, Y Yan, C Mao… - Nature …, 2022 - nature.com
Targeting ferroptosis, a unique cell death modality triggered by unrestricted lipid
peroxidation, in cancer therapy is hindered by our incomplete understanding of ferroptosis …

Inferring gene expression from cell-free DNA fragmentation profiles

MS Esfahani, EG Hamilton, M Mehrmohamadi… - Nature …, 2022 - nature.com
Profiling of circulating tumor DNA (ctDNA) in the bloodstream shows promise for
noninvasive cancer detection. Chromatin fragmentation features have previously been …

Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

MV Negrao, HA Araujo, G Lamberti, AJ Cooper… - Cancer discovery, 2023 - AACR
Molecular modifiers of KRASG12C inhibitor (KRASG12Ci) efficacy in advanced KRAS G12C-
mutant NSCLC are poorly defined. In a large unbiased clinicogenomic analysis of 424 …

Targeting NRF2 and its downstream processes: opportunities and challenges

L Torrente, GM DeNicola - Annual review of pharmacology and …, 2022 - annualreviews.org
The transcription factor NRF2 coordinates the expression of a vast array of cytoprotective
and metabolic genes in response to various stress inputs to restore cellular homeostasis …

NRF2: KEAPing tumors protected

R Pillai, M Hayashi, AM Zavitsanou… - Cancer Discovery, 2022 - AACR
The Kelch-like ECH-associated protein 1 (KEAP1)/nuclear factor erythroid 2–related factor 2
(NRF2) pathway plays a physiologic protective role against xenobiotics and reactive oxygen …

Role of NRF2 in lung cancer

M Sánchez-Ortega, AC Carrera, A Garrido - Cells, 2021 - mdpi.com
The gene expression program induced by NRF2 transcription factor plays a critical role in
cell defense responses against a broad variety of cellular stresses, most importantly …

Exosomal protein angiopoietin-like 4 mediated radioresistance of lung cancer by inhibiting ferroptosis under hypoxic microenvironment

Y Zhang, X Liu, L Zeng, X Zhao, Q Chen, Y Pan… - British Journal of …, 2022 - nature.com
Background Hypoxia-mediated radioresistance is a major reason for the adverse
radiotherapy outcome of non-small cell lung cancer (NSCLC) in clinical, but the underlying …

Activation of the NRF2 antioxidant program sensitizes tumors to G6PD inhibition

H Ding, Z Chen, K Wu, SM Huang, WL Wu… - Science …, 2021 - science.org
The KEAP1/NRF2 pathway promotes metabolic rewiring to support redox homeostasis.
Activation of NRF2 occurs in many cancers, often due to KEAP1 mutations, and is …